The AP2A1 Knockout HT29 Polyclonal Cells are a heterogeneous population of HT29 colorectal adenocarcinoma cells engineered to disrupt the AP2A1 gene via CRISPR/Cas9-mediated gene editing. This polyclonal knockout model provides a loss-of-function system to investigate the role of the alpha-adaptin A subunit of the AP-2 complex in endocytic trafficking and cellular signaling. The polyclonal nature ensures a spectrum of genotypes that mimics population diversity while maintaining overall target-gene disruption.
HT29 cells are a well-established human colorectal adenocarcinoma cell line derived from a primary tumor of a 44-year-old Caucasian female. They exhibit an adherent epithelial morphology and serve as a valuable model for intestinal epithelial biology, colorectal cancer pathogenesis, and drug response studies. The genetic background of HT29 includes mutations commonly found in colorectal cancer, such as in APC and TP53, making them particularly suitable for studying signaling pathways relevant to tumor progression and metastasis.
AP2A1 encodes alpha-adaptin A, a key subunit of the AP-2 adaptor complex that mediates cargo selection and clathrin-coated vesicle formation at the plasma membrane. The AP-2 complex interacts with clathrin triskelia, dynamin, and accessory adaptor proteins like DAB2, EPS15, HIP1, epsin, and amphiphysin to facilitate clathrin-dependent endocytosis. This process internalizes receptors such as EGFR, TfR, and LDLR, which contain YXX?? or dileucine sorting motifs. Upstream regulators include phosphoinositide PI(4,5)P2 and ARF6. Downstream, AP2A1-dependent endocytosis controls signaling via ERK and AKT, affecting cell proliferation, migration, and survival. Mechanistically, AP2A1 knockout disrupts AP-2 complex assembly, impairing clathrin-mediated endocytosis and leading to altered receptor trafficking and signaling dynamics.
In colorectal adenocarcinoma HT29 cells, AP2A1 knockout perturbs endocytosis-dependent signaling pathways critical for tumor cell behavior. Disruption of AP2A1 is expected to reduce internalization of growth factor receptors like EGFR, thereby modulating downstream ERK and AKT pathways that govern proliferation and survival. This knockout model enables investigation of how endocytic trafficking impacts colorectal cancer progression, including cell migration and metastasis. Furthermore, it provides a platform to study the role of the AP-2 complex in receptor-mediated signalling and may reveal compensatory mechanisms or vulnerabilities in colorectal cancer cells.
The AP2A1 Knockout HT29 Polyclonal Cells are suitable for a variety of experimental assays. Researchers can perform Western blotting to confirm AP2A1 loss, transferrin uptake assays to quantify clathrin-dependent endocytosis, and immunofluorescence to visualize clathrin and endosomal markers. Flow cytometry enables measurement of surface receptor levels, while cell proliferation and migration assays assess functional consequences. Co-immunoprecipitation can probe AP-2 complex integrity, and RNA-seq transcriptomics can reveal global expression changes. EGFR signaling phospho-arrays allow dissection of downstream signaling alterations. These applications support studies in endocytosis mechanisms, receptor trafficking, drug delivery and nanoparticle uptake, and adaptor protein functional analysis. For additional information, please contact Ascent Research.
